{
    "ticker": "ADIL",
    "name": "Adial Pharmaceuticals, Inc.",
    "description": "Adial Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development of innovative treatments for addictions and related disorders. Founded in 2017 and based in Charlottesville, Virginia, Adial is committed to improving the lives of patients suffering from alcohol use disorder (AUD) and other behavioral health conditions. The company\u2019s lead product candidate, AD04, is an investigational medication designed to reduce the craving for alcohol and prevent relapse in individuals with AUD. Adial's unique approach leverages a genetic testing platform to identify patients who are most likely to benefit from its therapies, enhancing treatment efficacy and safety. In addition to AD04, the company is exploring other indications related to addiction and weight management. With a focus on clinical development, Adial aims to bring innovative solutions to market that address unmet medical needs in the addiction treatment space. The company's mission is driven by a belief in the potential of targeted therapies to transform the treatment landscape for addiction, ultimately leading to better health outcomes and improved quality of life for patients.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Charlottesville, Virginia, USA",
    "founded": "2017",
    "website": "https://www.adialpharma.com",
    "ceo": "William Stilley",
    "social_media": {
        "twitter": "https://twitter.com/adialpharma",
        "linkedin": "https://www.linkedin.com/company/adial-pharmaceuticals-inc/"
    },
    "investor_relations": "https://www.adialpharma.com/investors",
    "key_executives": [
        {
            "name": "William Stilley",
            "position": "CEO"
        },
        {
            "name": "Cynthia A. Aiken",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Pharmaceuticals",
            "products": [
                "AD04"
            ]
        }
    ],
    "seo": {
        "meta_title": "Adial Pharmaceuticals, Inc. | Innovative Addiction Treatments",
        "meta_description": "Adial Pharmaceuticals, Inc. is dedicated to developing innovative therapies for addiction and related disorders. Learn about our lead product AD04 and our commitment to improving patient outcomes.",
        "keywords": [
            "Adial Pharmaceuticals",
            "AD04",
            "Alcohol Use Disorder",
            "Addiction Treatment",
            "Biopharmaceuticals"
        ]
    },
    "faq": [
        {
            "question": "What is Adial Pharmaceuticals focused on?",
            "answer": "Adial Pharmaceuticals is focused on developing innovative treatments for addictions and related disorders."
        },
        {
            "question": "What is AD04?",
            "answer": "AD04 is an investigational medication designed to reduce cravings for alcohol and prevent relapse in individuals with alcohol use disorder."
        },
        {
            "question": "Where is Adial Pharmaceuticals headquartered?",
            "answer": "Adial Pharmaceuticals is headquartered in Charlottesville, Virginia, USA."
        },
        {
            "question": "Who is the CEO of Adial Pharmaceuticals?",
            "answer": "William Stilley is the CEO of Adial Pharmaceuticals, Inc."
        },
        {
            "question": "When was Adial Pharmaceuticals founded?",
            "answer": "Adial Pharmaceuticals was founded in 2017."
        }
    ],
    "competitors": [
        "AXSM",
        "MNKD",
        "BLAE"
    ],
    "related_stocks": [
        "AMGN",
        "PFE",
        "JNJ",
        "GILD"
    ]
}